Clinical Trials

ACCESS TO THE LATEST

TREATMENTS

Oregon Urology Institute is committed to advancing the standard of care in treating urological disorders and cancers. To achieve this, we are deeply involved in clinical research, giving you access to experimental procedures and treatments that wouldn’t otherwise be available.

If you’d like to join one of our clinical trials, your doctor can help determine if you’re a candidate. Qualified candidates will be informed about potential risks and benefits. Our clinical trial participants are carefully monitored, and you can opt out at any time.

Currently

Enrolling

Here are trials we're currently conducting. Ask your doctor for more information if you're interested in participating.

Prostate Cancer- Lancelot
Official Title: Analyses of Plasma Samples from Patients with Metastatic Prostate Cancer to Support Analytical Validation of a Novel Liquid Based Companion in vitro Diagnostic Test
Prostate Cancer- Multiplatform-201601.PRO
Official Title:

Specimen Collection at Urology Practices for PSAII and fPSAII Assays on ADVIA® Centaur Systems and Atellica IM Analyzers

Prostate Cancer- Robust III
Study Type:
Interventional

Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment

Official Title: ROBUST III - Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease - A Randomized Control Trial
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- SAFELY
Study Type:
Observational

Study Design:
Observational Model: Cohort
Time Perspective: Prospective
Estimated Enrollment: 600 participants
Target Follow-Up Duration: 10 Years

Official Title:
A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- Tak-Rad
Study Type:
Interventional

Study Design:

  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Official Title: A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
For more information on this study, visit clinicaltrials.gov

Ongoing Studies

Not enrolling

Prostate Cancer- Atlas

Study Type:
Interventional

Study Design:
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Official Title:
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- ConfirmMDx

Official Title:
A prospective study to evaluate the clinical utility of the ConfirmMDx® for Prostate Cancer assay for men with previous histologically-negative prostate biopsies

Prostate Cancer- EMBARK

Study Type:
Interventional

Study Design:
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title:
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy)
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- GU-115

Study Type:
Interventional

Study Design:
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Official Title:
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- MOLE

Study Type:
Interventional

Study Design:
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment

Official Title:
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- PROSPER

Study Type:
Interventional

Study Design:
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title:
A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer.
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- ProVent
Study Type:

Interventional

Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized 2:1 to the sipuleucel-T arm or the control arm.Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals. Subjects randomized to the control arm will be followed on AS as standard of care described in the schedule of events.
Masking: None (Open Label)
Primary Purpose: Basic Science

Official Title:
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- REASSURE

Study Type:
Observational

Study Design:
Observational Model: Cohort
Time Perspective: Prospective

Official Title: Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC population for Long-term Evaluation
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- Titan
Study Type:
Interventional

Study Design:

  • Allocation: Randomized
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Parallel Assignment
  • Masking: Double Blind (Subject, Investigator)
  • Primary Purpose: Treatment

Official Title:
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- TRUMPET

Study Type:
Observational

Study Design:
Observational Model: Cohort
Time Perspective: Prospective

Official Title:
A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States
For more information on this study, visit clinicaltrials.gov

Prostate Cancer- Ulysses

Study Type:
Interventional

Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title:
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
For more information on this study, visit clinicaltrials.gov